Tanmoy Mondal to Xenograft Model Antitumor Assays
This is a "connection" page, showing publications Tanmoy Mondal has written about Xenograft Model Antitumor Assays.
Connection Strength
0.134
-
Shivange G, Mondal T, Lyerly E, Bhatnagar S, Landen CN, Reddy S, Kim J, Doan B, Riddle P, Tushir-Singh J. A patch of positively charged residues regulates the efficacy of clinical DR5 antibodies in solid tumors. Cell Rep. 2021 11 02; 37(5):109953.
Score: 0.047
-
Mitra S, Muralidharan SV, Di Marco M, Juvvuna PK, Kosalai ST, Reischl S, Jachimowicz D, Subhash S, Raimondi I, Kurian L, Huarte M, Kogner P, Fischer M, Johnsen JI, Mondal T, Kanduri C. Subcellular Distribution of p53 by the p53-Responsive lncRNA NBAT1 Determines Chemotherapeutic Response in Neuroblastoma. Cancer Res. 2021 03 15; 81(6):1457-1471.
Score: 0.044
-
Przanowski P, Lou S, Tihagam RD, Mondal T, Conlan C, Shivange G, Saltani I, Singh C, Xing K, Morris BB, Mayo MW, Teixeira L, Lehmann-Che J, Tushir-Singh J, Bhatnagar S. Oncogenic TRIM37 Links Chemoresistance and Metastatic Fate in Triple-Negative Breast Cancer. Cancer Res. 2020 11 01; 80(21):4791-4804.
Score: 0.043